Medical/Pharmaceuticals

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

SUZHOU, China, June 2, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for...

2022-06-02 08:08 3990

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares

SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...

2022-06-02 08:00 7437

Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific

EAST RUTHERFORD, NJ, June 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a leading pr...

2022-06-01 18:00 3488

PMB Announces EIT Health Supported FLASHKNiFE Consortium Towards the Clinical Application of FLASH Radiation Therapy

PEYNIER, France, June 1, 2022 /PRNewswire/ -- PMB announces the launch of the FLASHKNiFE Consortium, supported by the European Institute of Innovation & Technology for Health (EIT Health). This European public-private partnership aims at advancing radiation therapy by introducing a new radiothera...

2022-06-01 16:15 3693

Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

* LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research * Safety profile is favourable and consistent with previous HMTM studies * TauRx will now pursue regulatory ...

2022-06-01 16:00 2667

AMGEN AND NSG BIOLABS ANNOUNCE GOLDEN TICKET TO BOOST SINGAPORE'S BIOTECH ECOSYSTEM

Amgen is the inaugural sponsor of the NSG Tomorrow Programme that aims to support innovation among biotech startups inSoutheast Asia SINGAPORE, June 1, 2022 /PRNewswire/ -- Amgen , a leading global biotechnology company, andNSG BioLabs , Singapore's l...

2022-06-01 10:00 4445

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and toripalimab in patients with advanced solid tumors TORCH-2 is the world's first clinical study evaluating the combination of a dual mTORC1/2 inhibitor and an anti-PD-1 monoclonal antibody SHANGHAI ...

2022-06-01 08:30 4046

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-06-01 08:00 4534

Kemin Food Technologies - Asia Introduces Antimicrobial Disinfectant Solutions KEEPER™ and OXINE™

Latest product lines address safety at the start by treating food, water and the preparation space for food SINGAPORE, June 1, 2022 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world w...

2022-06-01 08:00 4352

CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights

SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results a...

2022-06-01 00:35 7190

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 5394

BIOMERICS ANNOUNCES EXPANSION INTO IRELAND

Expands High-Performance Balloon Design & Development Capabilities in Galway  SALT LAKE CITY, May 31, 2022 /PRNewswire/ -- Biomerics, the leading vertically integrated medical device contract manufacturer serving the interventional device market, has today announced the opening of a 2,000 sq. f...

2022-05-31 22:05 4885

Nalagenetics obtains CE Mark for its pharmacogenomics software, Nala Clinical Decision Support™ Module- PGx Core

SINGAPORE, May 31, 2022 /PRNewswire/ -- Nalagenetics has just completed CE-marking for one of the reporting modules of its Clinical Decision Support (CDS) software. The registration enables its software to be marketed in Europe and support further approval inSoutheast Asia, where it aims to gain...

2022-05-31 21:09 4045

Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai Announce Joint Center for Engineering and Precision Medicine

NEW YORK, May 31, 2022 /PRNewswire/ -- Rensselaer Polytechnic Institute and the Icahn School of Medicine atMount Sinai recently announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science ...

2022-05-31 21:00 4185

MGI and King Abdullah International Medical Research Center Announce Partnership for Genomic Research

The new agreement will enable cutting-edge research aimed at preventing disease and improving health while supporting specialized training of healthcare professionals and scientists. RIYADH, Saudi Arabia, May 31, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) and King...

2022-05-31 20:33 2790

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

MONTREAL, May 31, 2022 /PRNewswire/ -- Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye tracking technology for people living with...

2022-05-31 18:00 2475

Medical training in Vietnam impressively attracts international students.

HO CHI MINH CITY, Vietnam, May 30, 2022 /PRNewswire/ -- In the last few days of May, many colleagues fromIndia, Honduras, Nigeria, etc., came to Vietnam to be admitted to the Medical Major of Hong BangInternational University (HIU). This is a significant milestone for the Vietnamese board of educ...

2022-05-30 20:08 4170

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

GAITHERSBURG, Md. and SUZHOU, China, May 30, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the launch of a Phase I clinical trial of the Company's si...

2022-05-30 16:40 3785

Experts attending P&G Health's Global Webinar Series highlight underdiagnosis concerns as Peripheral Neuropathy becomes more prevalent

- Often underestimated and diagnosed late, increasing awareness and early-stage screening of Peripheral Neuropathy by primary care physicians can help prevent long-term complications and quality of life restrictions. - The Global Webinar Series for healthcare professionals has 'Virtual Pavilions...

2022-05-30 16:12 3299

RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

STOCKHOLM, May 30, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today onMay 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (on...

2022-05-30 11:04 2361
1 ... 317318319320321322323 ... 381

Week's Top Stories